5 Key Takeaways
-
1
The UK had 193 ongoing advanced therapy clinical trials in 2025, an increase from 187 in 2024.
-
2
56% of the trials were early-stage, and 80% were commercially sponsored.
-
3
The UK participated in 9% of global trials and 57% of European trials in 2025.
-
4
Over 80% of ATMP clinical trials focused on gene therapies, with oncology representing 35% of trials.
-
5
The UK is well-positioned for advanced therapy trials due to supportive regulations and increased NICE thresholds.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
